Woodline Partners’s ArriVent BioPharma AVBP Stock Holding History

Woodline Partners’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.41M	Buy	147,639 +253	+0.2%	+$5.71K	0.01%	726
2025 Q4	$2.97M	Sell	147,386 -149,530	-50%	-$3.11M	0.01%	718
2025 Q3	$5.48M	Buy	296,916 +150,000	+102%	+$2.95M	0.03%	544
2025 Q2	$3.2M	Buy	146,916 +543	+0.4%	+$11.3K	0.02%	642
2025 Q1	$2.71M	Buy	146,373 +576	+0.4%	+$14.1K	0.02%	620
2024 Q4	$3.88M	Buy	145,797 +24,853	+21%	+$714K	0.03%	535
2024 Q3	$2.84M	Buy	120,944 +20,944	+21%	+$475K	0.02%	444
2024 Q2	$1.85M	Hold	100,000	–	–	0.02%	423
2024 Q1	$1.79M	Buy	+100,000	New	+$2.02M	0.02%	430

Other funds holding AVBP

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners's AVBP Position: Q1 2026 in Review

Woodline Partners increased its ArriVent BioPharma (AVBP) stake by 0.17% in Q1 2026, buying an estimated $5.71K and bringing the position to 147,639 shares worth $3.41M. The position accounts for 0.01% of the portfolio, ranked #726.

Woodline Partners first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $5.48M in Q3 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

Woodline Partners held 147,639 shares of ArriVent BioPharma worth $3.41M as of Q1 2026.
Woodline Partners bought 253 ArriVent BioPharma shares in Q1 2026, an estimated $5.71K.
ArriVent BioPharma made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #726 holding.
Woodline Partners first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
Woodline Partners's ArriVent BioPharma position peaked at $5.48M in Q3 2025.
139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.